A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases

The cytokine interleukin-2 (IL-2) can stimulate both effector immune cells and regulatory T (Treg) cells. The ability of selectively engaging either of these effects has spurred interest in using IL-2 for immunotherapy of cancer and autoimmune diseases. Thus, numerous IL-2-based biologic agents with improved bias or delivery towards effector immune cells or Treg cells have been developed. This study systematically reviews clinical results of improved IL-2-based compounds.

We searched the ClinicalTrials.gov database for registered trials using improved IL-2-based agents and different databases for available results of these studies.